Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Bleomycin Sulphate
Capecitabine
Capecitabine (2)
Carboplatin
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Docetaxelum
Doxorubicinum
Epirubicinum
Etoposidum
Fluorouracilum
Ifosfamidum
Imatinibum
Irinotecanum
Lanreotidum
Octreotidum
Oxaliplatinum
Oxaliplatinum (2)
Paclitaxel
Sorafenib
Sunitinib
Temozolomidum
Trastuzumabum I.v.
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- gastric cancer
- esophageal cancer
- » A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
- » Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults
- » A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
- » A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
- » A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)